Sign In

Login

Password

Forgot Password ? Sign Up

Kabozantynib (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Kabozantynib" in Polish language version.

refsWebsite
Global rank Polish rank
28doi.org
2nd place
6th place
28nih.gov
4th place
7th place
2web.archive.org
1st place
1st place
2europa.eu
68th place
31st place

doi.org

  • A. Bharthuar. Metastatic renal cell carcinoma: Current scenario and future trends. „South Asian J Cancer”. 1 (1), s. 30-35, 2012. DOI: 10.4103/2278-330X.96505. PMID: 24455506. 
  • A. Abdelaziz, U. Vaishampayan. Cabozantinib for the treatment of kidney cancer. „Expert Rev Anticancer Ther”. 17 (7), s. 577-584, 2017. DOI: 10.1080/14737140.2017.1344553. PMID: 28633552. 
  • J. M. Ruiz-Morales, D. Y. Heng. Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. „Ther Adv Urol”. 8 (6), s. 338-347, 2016. DOI: 10.1177/1756287216663073. PMID: 27904650. 
  • S. Osanto, T. van der Hulle. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. „Ther Adv Urol”. 10 (3), s. 109-123, 2018. DOI: 10.1177/1756287217748867. PMID: 29662541. 
  • N. M. Tannir, G. Schwab, V. Grünwald. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. „Curr Oncol Rep”. 19 (2), s. 14, 2017. DOI: 10.1007/s11912-017-0566-9. PMID: 28247252. 
  • P. Grassi, E. Verzoni, R. Ratta, A. Mennitto i inni. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. „Drug Des Devel Ther”. 10, s. 2167-2172, 2016. DOI: 10.2147/DDDT.S104225. PMID: 27462141. 
  • S. S. Yu, D. I. Quinn, T. B. Dorff. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. „Onco Targets Ther”. 9, s. 5825-5837, 2016. DOI: 10.2147/OTT.S97397. PMID: 27713636. 
  • J. Krajewska, T. Olczyk, B. Jarzab. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. „Expert Rev Clin Pharmacol”. 9 (1), s. 69-79, 2016. DOI: 10.1586/17512433.2016.1102052. PMID: 26536165. 
  • C. D. Hart, R. H. De Boer. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. „Onco Targets Ther”. 6, s. 1-7, 2013. DOI: 10.2147/OTT.S27671. PMID: 23319867. 
  • M. Bersanelli, S. Buti. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. „Ther Adv Med Oncol”. 9 (10), s. 627-636, 2017. DOI: 10.1177/1758834017724314. PMID: 28974985. 
  • C. Grüllich. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. „Recent Results Cancer Res”. 201, s. 207-214, 2014. DOI: 10.1007/978-3-642-54490-3_12. PMID: 24756794. 
  • K. E. Torres, Q. S. Zhu, K. Bill, G. Lopez i inni. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. „Clin Cancer Res”. 17 (12), s. 3943-3955, 2011. DOI: 10.1158/1078-0432.CCR-11-0193. PMID: 21540237. 
  • F. M. Yakes, J. Chen, J. Tan, K. Yamaguchi i inni. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. „Mol Cancer Ther”. 10 (12), s. 2298-2308, 2011. DOI: 10.1158/1535-7163.MCT-11-0264. PMID: 21926191. 
  • Z. Xie, Y. H. Lee, M. Boeke, LB. Jilaveanu i inni. MET Inhibition in Clear Cell Renal Cell Carcinoma. „J Cancer”. 7 (10), s. 1205-1514, 2016. DOI: 10.7150/jca.14604. PMID: 27390595. 
  • Z, T. Al-Salama, G. M. Keating. Cabozantinib: A Review in Advanced Renal Cell Carcinoma. „Drugs”. 76 (18), s. 1771-1778, 2016. DOI: 10.1007/s40265-016-0661-5. PMID: 27909994. 
  • L. Zhou, X. D. Liu, M. Sun, X. Zhang i inni. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. „Oncogene”. 35 (21), s. 2687-2697, 2016. DOI: 10.1038/onc.2015.343. PMID: 26364599. 
  • T. K. Choueiri, B. Escudier, T. Powles, P. N. Mainwaring i inni. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. „N Engl J Med”. 373 (19), s. 1814-1823, 2015. DOI: 10.1056/NEJMoa1510016. PMID: 26406150. 
  • T. K. Choueiri, B. Escudier, T. Powles, N. M. Tannir i inni. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. „Lancet Oncol”. 17 (7), s. 917-927, 2016. DOI: 10.1016/S1470-2045(16)30107-3. PMID: 27279544. 
  • T. K. Choueiri, S. Halabi, B. L. Sanford, O. Hahn i inni. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. „J Clin Oncol”. 35 (6), s. 591-597, 2017. DOI: 10.1200/JCO.2016.70.7398. PMID: 28199818. 
  • T. K. Choueiri, C. Hessel, S. Halabi, B. Sanford i inni. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. „Eur J Cancer”. 94, s. 115-125, 2018. DOI: 10.1016/j.ejca.2018.02.012. PMID: 29550566. 
  • J. N. Markowitz, K. M. Fancher. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. „Pharmacotherapy”. 38 (3), s. 357-369, 2018. DOI: 10.1002/phar.2076. PMID: 29283440. 
  • R. Elisei, M. J. Schlumberger, S. P. Müller, P. Schöffski i inni. Cabozantinib in progressive medullary thyroid cancer. „J Clin Oncol”. 31 (29), s. 3639-3646, 2013. DOI: 10.1200/JCO.2012.48.4659. PMID: 24002501. 
  • M. Schlumberger, R. Elisei, S. Müller, P. Schöffski i inni. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. „Ann Oncol”. 28 (11), s. 2813-2819, 2017. DOI: 10.1093/annonc/mdx479. PMID: 29045520. 
  • A. Drilon, L. Wang, A. Hasanovic, Y. Suehara i inni. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. „Cancer Discov”. 3 (6), s. 630-635, 2013. DOI: 10.1158/2159-8290.CD-13-0035. PMID: 23533264. 
  • A. Drilon, N. Rekhtman, M. Arcila, L. Wang i inni. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. „Lancet Oncol”. 17 (12), s. 1653-1660, 2016. DOI: 10.1016/S1470-2045(16)30562-9. PMID: 27825636. 
  • M. Song, S. H. Kim, S. K. Yoon. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning. „Arch Pharm Res”. 38 (12), s. 2120-2123, 2015. DOI: 10.1007/s12272-015-0660-1. PMID: 26377589. 
  • R. Ferrara, N. Auger, E. Auclin, B. Besse. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. „J Thorac Oncol”. 13 (1), s. 27-45, 2018. DOI: 10.1016/j.jtho.2017.10.021. PMID: 29128428. 
  • J. W. Neal, S. E. Dahlberg, H. A. Wakelee, S. C. Aisner i inni. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. „Lancet Oncol”. 17 (12), s. 1661-1671, 2016. DOI: 10.1016/S1470-2045(16)30561-7. PMID: 27825638. 

europa.eu

ema.europa.eu

nih.gov

ncbi.nlm.nih.gov

  • A. Bharthuar. Metastatic renal cell carcinoma: Current scenario and future trends. „South Asian J Cancer”. 1 (1), s. 30-35, 2012. DOI: 10.4103/2278-330X.96505. PMID: 24455506. 
  • A. Abdelaziz, U. Vaishampayan. Cabozantinib for the treatment of kidney cancer. „Expert Rev Anticancer Ther”. 17 (7), s. 577-584, 2017. DOI: 10.1080/14737140.2017.1344553. PMID: 28633552. 
  • J. M. Ruiz-Morales, D. Y. Heng. Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. „Ther Adv Urol”. 8 (6), s. 338-347, 2016. DOI: 10.1177/1756287216663073. PMID: 27904650. 
  • S. Osanto, T. van der Hulle. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. „Ther Adv Urol”. 10 (3), s. 109-123, 2018. DOI: 10.1177/1756287217748867. PMID: 29662541. 
  • N. M. Tannir, G. Schwab, V. Grünwald. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. „Curr Oncol Rep”. 19 (2), s. 14, 2017. DOI: 10.1007/s11912-017-0566-9. PMID: 28247252. 
  • P. Grassi, E. Verzoni, R. Ratta, A. Mennitto i inni. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. „Drug Des Devel Ther”. 10, s. 2167-2172, 2016. DOI: 10.2147/DDDT.S104225. PMID: 27462141. 
  • S. S. Yu, D. I. Quinn, T. B. Dorff. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. „Onco Targets Ther”. 9, s. 5825-5837, 2016. DOI: 10.2147/OTT.S97397. PMID: 27713636. 
  • J. Krajewska, T. Olczyk, B. Jarzab. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. „Expert Rev Clin Pharmacol”. 9 (1), s. 69-79, 2016. DOI: 10.1586/17512433.2016.1102052. PMID: 26536165. 
  • C. D. Hart, R. H. De Boer. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. „Onco Targets Ther”. 6, s. 1-7, 2013. DOI: 10.2147/OTT.S27671. PMID: 23319867. 
  • M. Bersanelli, S. Buti. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. „Ther Adv Med Oncol”. 9 (10), s. 627-636, 2017. DOI: 10.1177/1758834017724314. PMID: 28974985. 
  • C. Grüllich. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. „Recent Results Cancer Res”. 201, s. 207-214, 2014. DOI: 10.1007/978-3-642-54490-3_12. PMID: 24756794. 
  • K. E. Torres, Q. S. Zhu, K. Bill, G. Lopez i inni. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. „Clin Cancer Res”. 17 (12), s. 3943-3955, 2011. DOI: 10.1158/1078-0432.CCR-11-0193. PMID: 21540237. 
  • F. M. Yakes, J. Chen, J. Tan, K. Yamaguchi i inni. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. „Mol Cancer Ther”. 10 (12), s. 2298-2308, 2011. DOI: 10.1158/1535-7163.MCT-11-0264. PMID: 21926191. 
  • Z. Xie, Y. H. Lee, M. Boeke, LB. Jilaveanu i inni. MET Inhibition in Clear Cell Renal Cell Carcinoma. „J Cancer”. 7 (10), s. 1205-1514, 2016. DOI: 10.7150/jca.14604. PMID: 27390595. 
  • Z, T. Al-Salama, G. M. Keating. Cabozantinib: A Review in Advanced Renal Cell Carcinoma. „Drugs”. 76 (18), s. 1771-1778, 2016. DOI: 10.1007/s40265-016-0661-5. PMID: 27909994. 
  • L. Zhou, X. D. Liu, M. Sun, X. Zhang i inni. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. „Oncogene”. 35 (21), s. 2687-2697, 2016. DOI: 10.1038/onc.2015.343. PMID: 26364599. 
  • T. K. Choueiri, B. Escudier, T. Powles, P. N. Mainwaring i inni. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. „N Engl J Med”. 373 (19), s. 1814-1823, 2015. DOI: 10.1056/NEJMoa1510016. PMID: 26406150. 
  • T. K. Choueiri, B. Escudier, T. Powles, N. M. Tannir i inni. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. „Lancet Oncol”. 17 (7), s. 917-927, 2016. DOI: 10.1016/S1470-2045(16)30107-3. PMID: 27279544. 
  • T. K. Choueiri, S. Halabi, B. L. Sanford, O. Hahn i inni. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. „J Clin Oncol”. 35 (6), s. 591-597, 2017. DOI: 10.1200/JCO.2016.70.7398. PMID: 28199818. 
  • T. K. Choueiri, C. Hessel, S. Halabi, B. Sanford i inni. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. „Eur J Cancer”. 94, s. 115-125, 2018. DOI: 10.1016/j.ejca.2018.02.012. PMID: 29550566. 
  • J. N. Markowitz, K. M. Fancher. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. „Pharmacotherapy”. 38 (3), s. 357-369, 2018. DOI: 10.1002/phar.2076. PMID: 29283440. 
  • R. Elisei, M. J. Schlumberger, S. P. Müller, P. Schöffski i inni. Cabozantinib in progressive medullary thyroid cancer. „J Clin Oncol”. 31 (29), s. 3639-3646, 2013. DOI: 10.1200/JCO.2012.48.4659. PMID: 24002501. 
  • M. Schlumberger, R. Elisei, S. Müller, P. Schöffski i inni. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. „Ann Oncol”. 28 (11), s. 2813-2819, 2017. DOI: 10.1093/annonc/mdx479. PMID: 29045520. 
  • A. Drilon, L. Wang, A. Hasanovic, Y. Suehara i inni. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. „Cancer Discov”. 3 (6), s. 630-635, 2013. DOI: 10.1158/2159-8290.CD-13-0035. PMID: 23533264. 
  • A. Drilon, N. Rekhtman, M. Arcila, L. Wang i inni. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. „Lancet Oncol”. 17 (12), s. 1653-1660, 2016. DOI: 10.1016/S1470-2045(16)30562-9. PMID: 27825636. 
  • M. Song, S. H. Kim, S. K. Yoon. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning. „Arch Pharm Res”. 38 (12), s. 2120-2123, 2015. DOI: 10.1007/s12272-015-0660-1. PMID: 26377589. 
  • R. Ferrara, N. Auger, E. Auclin, B. Besse. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. „J Thorac Oncol”. 13 (1), s. 27-45, 2018. DOI: 10.1016/j.jtho.2017.10.021. PMID: 29128428. 
  • J. W. Neal, S. E. Dahlberg, H. A. Wakelee, S. C. Aisner i inni. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. „Lancet Oncol”. 17 (12), s. 1661-1671, 2016. DOI: 10.1016/S1470-2045(16)30561-7. PMID: 27825638. 

web.archive.org